---
title: "Canopy Growth Corporation (CGC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CGC.US.md"
symbol: "CGC.US"
name: "Canopy Growth Corporation"
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:57:15.252Z"
locales:
  - [en](https://longbridge.com/en/quote/CGC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CGC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CGC.US.md)
---

# Canopy Growth Corporation (CGC.US)

## Company Overview

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.canopygrowth.com](https://www.canopygrowth.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 79 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.23% |  |
| Net Profit YoY | 31.03% |  |
| P/B Ratio | 0.72 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 400002042.10 |  |
| Revenue | 200533493.33 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -48.50% | E |
| Profit Margin | -117.31% | E |
| Gross Margin | 28.80% | C |
| Revenue YoY | -0.23% | D |
| Net Profit YoY | 31.03% | B |
| Total Assets YoY | -0.42% | D |
| Net Assets YoY | 34.34% | A |
| Cash Flow Margin | 24.10% | D |
| OCF YoY | -0.23% | D |
| Turnover | 0.25 | D |
| Gearing Ratio | 31.46% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Canopy Growth Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.23%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "31.03%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.72",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "400002042.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "200533493.33",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-48.50%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-117.31%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "28.80%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.23%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.03%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.42%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "24.10%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-0.23%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.25",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "31.46%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.70 | 127/189 | - | - | - |
| PB | 0.72 | 29/189 | 1.04 | 0.79 | 0.68 |
| PS (TTM) | 1.99 | 56/189 | 2.25 | 2.02 | 1.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 14% |
| Overweight | 1 | 14% |
| Hold | 4 | 57% |
| Underweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.99 |
| Highest Target | 1.79 |
| Lowest Target | 1.79 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CGC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CGC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CGC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CGC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**